The National Cancer Institute awarded the Institute for Systems Biology (ISB) a 5-year, $13 million grant to lead a collaborative cancer center and study sequential combinations of targeted inhibitors and immunotherapies.
The program – called Spatiotemporal Tumor Analytics for Guiding Sequential Targeted Inhibitor-Immunotherapy Combinations, or ST-Analytics – is designed to determine if the treatments yield greater patient benefit when administered in sequence rather than as monotherapies or as simultaneously administered combinations.
